Use of Robust Classification Techniques for the Prediction of Human Cytochrome P450 2D6 Inhibition

A new in silico model is developed to predict cytochrome P450 2D6 inhibition from 2D chemical structure. Using a diverse training set of 100 compounds with published inhibition constants, an ensemble approach to recursive partitioning is applied to create a large number of classification trees, each of which yields a yes/no prediction about inhibition for a given compound. These binary classifications are combined to provide an overall prediction, which answers the yes/no question about inhibition and provides a measure of confidence about that prediction. Compared to single-tree models, the ensemble approach is less sensitive to noise in the experimental data as well as to changes in the training set. Internal validation tests indicated an overall classification accuracy of 75%, whereas predictions applied to an external set of 51 compounds yielded 80% accuracy, with all inhibitors correctly identified. The speed and 2D nature of this model make it appropriate for high-throughput processing of large chemical libraries, and the confidence level provides a continuous scale on which to prioritize compounds.

[1]  F. Gonzalez,et al.  Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450 , 2000, Xenobiotica; the fate of foreign compounds in biological systems.

[2]  R H Levy,et al.  Influence of stiripentol on cytochrome P450‐mediated metabolic pathways in humans: In vitro and in vivo comparison and calculation of in vivo inhibition constants , 1997, Clinical pharmacology and therapeutics.

[3]  S. Grimm,et al.  Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[4]  R H Levy,et al.  Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[5]  R. Tyndale,et al.  Inhibition of cytochromes P450 by antifungal imidazole derivatives. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[6]  S. Imaoka,et al.  Mepyramine, a histamine H1 receptor antagonist, inhibits the metabolic activity of rat and human P450 2D forms. , 1995, The Journal of pharmacology and experimental therapeutics.

[7]  H. Yamazaki,et al.  Inhibitory effects of azelastine and its metabolites on drug oxidation catalyzed by human cytochrome P-450 enzymes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[8]  B H Arison,et al.  In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[9]  N. Vermeulen,et al.  Computer prediction and experimental validation of cytochrome P4502D6-dependent oxidation of GBR 12909. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[10]  Elizabeth Landrum Michalets,et al.  Update: Clinically Significant Cytochrome P‐450 Drug Interactions , 1998, Pharmacotherapy.

[11]  D. Flockhart,et al.  Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[12]  S. Webber,et al.  Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[13]  D McKillop,et al.  Preclinical and in vitro assessment of the potential of D0870, an antifungal agent, for producing clinical drug interactions. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.

[14]  E. Kharasch,et al.  Lack of single-dose disulfiram effects on cytochrome P-450 2C9, 2C19, 2D6, and 3A4 activities: evidence for specificity toward P-450 2E1. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[15]  C. Masimirembwa,et al.  Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[16]  Zeruesenay Desta,et al.  The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[17]  A. D. Rodrigues,et al.  Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. , 1996, The Journal of pharmacology and experimental therapeutics.

[18]  M. Eichelbaum,et al.  The metabolism of aprindine in relation to the sparteine/debrisoquine polymorphism. , 1993, British journal of clinical pharmacology.

[19]  G. Gervasini,et al.  Tryptamine: a possible endogenous substrate for CYP2D6. , 1997, Pharmacogenetics.

[20]  D. Flockhart,et al.  In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6. , 2000, British journal of clinical pharmacology.

[21]  L. Bertilsson,et al.  Polymorphic debrisoquin hydroxylation in 757 Swedish subjects , 1988, Clinical pharmacology and therapeutics.

[22]  R. Kauffman,et al.  Investigation of terbinafine as a CYP2D6 inhibitor in vivo , 1999, Clinical pharmacology and therapeutics.

[23]  A. Vickers,et al.  In vitro metabolism of tegaserod in human liver and intestine: assessment of drug interactions. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[24]  J S Harmatz,et al.  Inhibition of cytochrome P450 by nefazodone in vitro: studies of dextromethorphan O- and N-demethylation. , 2003, British journal of clinical pharmacology.

[25]  J. Scatina,et al.  Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. , 1997, British journal of clinical pharmacology.

[26]  F. Guengerich,et al.  Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies. , 1993, Journal of medicinal chemistry.

[27]  P. Robertson,et al.  In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[28]  J S Harmatz,et al.  Appetite suppressant drugs as inhibitors of human cytochromes P450: in vitro inhibition of P450-2D6 by D- and L-fenfluramine, but not phentermine. , 1998, Journal of clinical psychopharmacology.

[29]  R L Slaughter,et al.  Recent Advances: the Cytochrome P450 Enzymes , 1995, The Annals of pharmacotherapy.

[30]  S Jaruratanasirikul,et al.  The inhibitory effect of amiodarone and desethylamiodarone on dextromethorphan O‐demethylation in human and rat liver microsomes , 1994, The Journal of pharmacy and pharmacology.

[31]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[32]  C. Beasley,et al.  Olanzapine. Pharmacokinetic and pharmacodynamic profile. , 1999, Clinical pharmacokinetics.

[33]  L. Wienkers,et al.  Cytochrome P-450-mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[34]  R. Obach,et al.  Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression. , 2000, The Journal of pharmacology and experimental therapeutics.

[35]  H. Yamazaki,et al.  Inhibition and inactivation of human cytochrome P450 isoforms by phenethyl isothiocyanate. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[36]  Edoardo Spina,et al.  Inhibition of Risperidone Metabolism by Fluoxetine in Patients With Schizophrenia: A Clinically Relevant Pharmacokinetic Drug Interaction , 2002, Journal of clinical psychopharmacology.

[37]  S. L. Dixon,et al.  One-dimensional molecular representations and similarity calculations: methodology and validation. , 2001, Journal of medicinal chemistry.

[38]  M. Kinter,et al.  Atypical metabolism of deprenyl and its enantiomer, (S)-(+)-N,alpha-dimethyl-N-propynylphenethylamine, by cytochrome P450 2D6. , 1994, Chemical research in toxicology.

[39]  J S Harmatz,et al.  Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. , 1994, The Journal of pharmacology and experimental therapeutics.

[40]  E. Sellers,et al.  Venlafaxine oxidation in vitro is catalysed by CYP2D6. , 1996, British journal of clinical pharmacology.

[41]  W. Trager,et al.  In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[42]  P. Collart,et al.  In vitro inhibition of human liver drug metabolizing enzymes by second generation antihistamines. , 1999, Chemico-biological interactions.

[43]  V. Fischer,et al.  The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[44]  D. Tweedie,et al.  Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. , 2000, British journal of clinical pharmacology.

[45]  J. A. Carrillo,et al.  Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2‐receptor antagonists , 1999, Clinical pharmacology and therapeutics.

[46]  D A Smith,et al.  An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems. , 1995, British journal of clinical pharmacology.

[47]  B. Drolet,et al.  In vitro characterization of cytochrome P450 2D6 inhibition by classic histamine H1 receptor antagonists. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[48]  Steven L. Dixon,et al.  Investigation of classification methods for the prediction of activity in diverse chemical libraries , 1999, J. Comput. Aided Mol. Des..

[49]  T. Yanagisawa,et al.  Metabolism of ipecac alkaloids cephaeline and emetine by human hepatic microsomal cytochrome P450s, and their inhibitory effects on P450 enzyme activities. , 2001, Biological & pharmaceutical bulletin.

[50]  V. Fischer,et al.  The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6. , 1992, The Journal of pharmacology and experimental therapeutics.

[51]  D. Flockhart,et al.  Identification and characterization of human cytochrome P450 isoforms interacting with pimozide. , 1998, The Journal of pharmacology and experimental therapeutics.

[52]  David A. Flockhart,et al.  Inhibition of Cytochrome P450 (CYP450) Isoforms by Isoniazid: Potent Inhibition of CYP2C19 and CYP3A , 2001, Antimicrobial Agents and Chemotherapy.

[53]  J. Sinclair,et al.  Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[54]  B. Sproule,et al.  Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone. , 1993, British journal of clinical pharmacology.

[55]  Rodrigues Ad,et al.  The in vitro interaction of dexmedetomidine with human liver microsomal cytochrome P4502D6 (CYP2D6). , 1997 .

[56]  D A Smith,et al.  Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide. In vitro studies and correlation with in vivo data. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[57]  L. Wienkers,et al.  Interaction of delavirdine with human liver microsomal cytochrome P450: inhibition of CYP2C9, CYP2C19, and CYP2D6. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[58]  U. Christians,et al.  In vitro evaluation of the disposition of A novel cysteine protease inhibitor. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[59]  D. Greenblatt,et al.  Inhibition of Human Cytochrome P450 Isoforms by Nonnucleoside Reverse Transcriptase Inhibitors , 2001, Journal of clinical pharmacology.